obesity drug glp-1 news today Chart: 1 in 8 Americans Now Use Drugs for Weight Loss The GLP-1 Access Gap: Mapping

No major drug interaction database flags naltrexone and semaglutide as contraindicated, but this does not mean the combination is universally appropriate

Conflict of interest BG has served as a consultant for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck (MSD) and Novartis as manufacturers of DPP-4 inhibitors and has received honoraria from these companies for lectures

This medication has a broad range of effects because it can attach to different receptors

Most of these diseases are interrelated, with glycemic control and weight loss being a major factor in improving the overall health of sufferers

It is in the same class as semaglutide, the active ingredient in Ozempic and Wegovy

Taking a GLP-1 medication plus a hypothetical GIP medication separately wouldnt necessarily produce the same effects as a designed dual agonist, and this approach hasnt been studied